Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The anaerobic spirochete causes intestinal spirochetosis, characterized by the intimate attachment of bacterial cells to the colonic mucosa, potentially leading to symptoms such as diarrhea, abdominal pain, and weight loss. Despite the clinical significance of infections, the mechanism of the interaction between and the colon epithelium is not known. We characterized the molecular mechanism of the -epithelium interaction and its impact on the epithelial barrier during infection. Through a proteomics approach, we identified BPP43_05035 as a candidate surface protein that mediates bacterial attachment to cultured human colonic epithelial cells. The crystal structure of BPP43_05035 revealed a globular lipoprotein with a six-bladed beta-propeller domain. Blocking the native BPP43_05035 on , either with a specific antibody or via competitive inhibition, abrogated its binding to epithelial cells, which required cell surface-exposed -glycans. Proximity labeling and interaction assays revealed that BPP43_05035 bound to tight junctions, thereby increasing the permeability of the epithelial monolayer. Extending our investigation to humans, we discovered a downregulation of tight junction and brush border genes in -infected patients carrying detectable levels of epithelium-bound BPP43_05035. Collectively, our findings identify BPP43_05035 as a adhesin that weakens the colonic epithelial barrier during infection.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444514PMC
http://dx.doi.org/10.1080/19490976.2024.2409247DOI Listing

Publication Analysis

Top Keywords

epithelial barrier
12
barrier infection
12
adhesin weakens
8
colonic epithelial
8
epithelial cells
8
bpp43_05035
7
epithelial
6
bpp43_05035 cell
4
cell surface
4
surface adhesin
4

Similar Publications

Role of PAI-1 in the progression and treatment resistance of non-small cell lung cancer.

Biomed J

September 2025

Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University. Electronic address:

Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Although immune checkpoint inhibitors (ICIs), chemotherapy, and molecular targeted therapies have improved survival rates, therapeutic resistance remains a major barrier to curative outcomes. Recently, plasminogen activator inhibitor-1 (PAI-1) has been implicated in lung cancer progression and treatment resistance.

View Article and Find Full Text PDF

Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), is characterized by disruption of intestinal barrier function and complex inflammatory manifestations locally and systemically. Although anti-tumor necrosis factor-α (TNF-α) agents such as Infliximab (IFX) are effective in treating IBD, their intestinal tissue concentration has been regarded as determinant of therapeutic efficacy while was restrained by the large molecular weight. Considering the enhanced expression of human neonatal Fc receptor (hFcRn) in UC tissues, we attempted to deliver the therapeutic entity of IFX into UC tissues by developing a novel dual-acting IFX Fab-F8 (IFX-F8) fusion protein for UC treatment.

View Article and Find Full Text PDF

Innovative engineering approaches to model host-microbiome interactions in vitro.

Adv Drug Deliv Rev

September 2025

J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States; Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States. Electronic address:

The human microbiome plays a critical role in health and disease. Disruptions in microbiota composition or function have been implicated not only as markers but also as drivers of diverse pathologies, creating opportunities for targeted microbiome interventions. Advancing these therapies requires experimental models that can unravel the complex, bidirectional interactions between human tissue and microbial communities.

View Article and Find Full Text PDF

Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment.

J Control Release

September 2025

Department of Pharmaceutics, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou City, Zhejiang Province 325035, China. Electronic address:

Gut barrier loss exacerbated gut microbiota dysbiosis by permitting pathogenic blooms, while gut microbiota dysbiosis caused the development of gut mucosal wounds by reducing mucus and breaking down epithelial tight junction. Current therapies combating colitis often fail to address both gut barrier dysfunction and microbial imbalance. Herein, inspired by natural gut mucus, a dual-crosslinked hydrogel (HSMP-LA) composed of thiol/maleimide-modified hyaluronic acid together with co-loading of antimicrobial ε-polylysine (ε-PL) and larazotide acetate (LA) had been developed as an injectable artificial gut mucus to simultaneously restore barrier integrity and modulate gut microbiota.

View Article and Find Full Text PDF

Ulcerative colitis (UC) is a persistent inflammatory condition marked by the destruction of the intestinal mucosal barrier, infiltration of inflammatory cells, and ulceration. M1/M2 macrophage polarization plays an imperative function in the regulation of inflammation through the nuclear factor-kappa B (NFκB) signaling pathway and modulating microRNA-155 (miR-155). Recent studies have highlighted the anti-ulcerogenic and colo-protective properties of sodium-glucose co-transporter-2 (SGLT2) inhibitors.

View Article and Find Full Text PDF